Articles tagged with Hiv Research
A survey of patients who experienced adverse events during hospitalization found that those disclosed to were twice as likely to rank their care as good or excellent. Disclosure was associated with improved patient perceptions of higher-quality care, even when the event was preventable.
Researchers will use web-based, patient-controlled personal health records to improve health and HIV prevention outcomes for HIV positive patients. The studies aim to assess the effectiveness of mobile phone text messages and a strategy called SBIRT in reducing drug and alcohol use and improving antiretroviral medication adherence.
The University of Alabama at Birmingham has been awarded $11.5 million to identify adolescents and young adults infected with HIV and link them to medical care. The grants will focus on two initiatives: improving HIV testing in youth and developing behavioral strategies for prevention.
A study published in PLoS Medicine suggests that reducing dropout rates from HIV treatment programs can lead to improved patient survival and cost-effectiveness. The researchers propose strategies such as eliminating co-payments for treatment and increasing services available to patients, which could form part of the commitment to star...
Researchers argue that concurrency is not a major driver of the HIV epidemic in sub-Saharan Africa due to lack of conclusive evidence. They suggest that other factors are more likely to contribute to the spread of the virus, and recommend further research initiatives.
A UCLA study found that HIV stigma is a strong predictor of poor access to medical care and suboptimal adherence to antiretroviral therapy. Individuals experiencing high levels of internalized stigma were more likely to report poor access to care and lower medication adherence.
HIV-infected patients are at higher risk for certain non-AIDS-defining malignancies such as anal, lung, Hodgkin's, melanoma and liver cancer. Researchers found a 60% increase in the incidence of these cancers among HIV-positive patients compared to those without HIV.
A US-led clinical trial in Thailand has found that an investigational vaccine regimen reduced the risk of HIV infection by 31% among vaccinated participants. The study, which enrolled over 16,000 adults, suggests a promising approach to preventing HIV transmission.
Researchers found that HIV can mutate its outer proteins to disguise itself from neutralizing antibodies, allowing it to escape the immune system. In two patients, viruses mutated parts of their outer proteins, interfering with antibody attack or targeting a different protein.
The VOICE study aims to evaluate the safety and effectiveness of two ARV regimens: daily vaginal gel and daily oral tablets, to reduce HIV risk in women. The trial will enroll up to 5,000 participants across four countries and assess their willingness to use the methods.
The Medical College of Wisconsin's Center for AIDS Intervention Research received a five-year, $11.16 million grant from the National Institutes of Health to continue its HIV prevention research. The center will focus on high-risk population segments in the US and expand international HIV prevention programs.
Researchers at UC Santa Cruz are working on a new approach to AIDS vaccine development using novel HIV protein structures and broadly neutralizing antibodies to combat the virus' high variability. The $3.5 million NIH grant will support studies exploring these promising findings and potentially lead to more effective vaccines.
Researchers at UAB found that preventive antibiotic TB therapy for HIV-infected patients is approximately $950 per case, compared to a previously reported range of $900-$1500 for treating new smear-positive TB cases. The integrated care approach also offers economic benefits by reducing productivity losses and preventing the spread of TB.
A five-year grant will create a comprehensive research infrastructure in the Midwest, focusing on HIV prevention, detection, and treatment. The center will concentrate its investigations around three themes: HIV and women, HIV and aging, and HIV and drug abuse.
Two new broadly neutralizing antibodies (bNAbs) have been discovered to target the HIV virus, providing a promising lead for AIDS vaccine development. The newly found antibodies, PG9 and PG16, attach to a novel site on the virus, making them more accessible for vaccine design.
Researchers have identified two powerful new antibodies to HIV that reveal a potential Achilles heel on the virus. The discovery offers new avenues for designing an effective AIDS vaccine and may lead to the identification of additional vulnerabilities in the virus.
For the first time, researchers have induced antibodies that neutralize HIV-1 and simultaneously recognize both HIV-1 envelope protein and lipids. The study employed widely used, clinically acceptable, well-tolerated and relatively inexpensive generic antigen-adjuvant constituents.
A new study from UCSF found a high HIV infection rate among gay-identified men in Soweto Township, with 33.9% of participants infected. The study also highlights the importance of targeted prevention and treatment for this population.
Researchers at the University of Illinois Chicago are developing an educational comic book to teach AIDS patients about food safety, highlighting risks such as listeria and toxoplasmosis. The study aims to improve awareness and reduce life-threatening infections among AIDS patients.
The article discusses South Africa's paradox of poor health outcomes amidst high health expenditures and supportive programmes. The authors identify leadership, innovation, and priority actions needed to achieve better health outcomes and tackle pressing challenges such as HIV/AIDS and non-communicable diseases.
Researchers at Yerkes National Primate Research Center propose alternative approaches to developing an effective AIDS vaccine, including making infected individuals resistant to disease progression or reducing the number of cells the virus can infect. They draw inspiration from African nonhuman primates that adapt to HIV-like viruses i...
Researchers at the University of North Carolina have decoded the entire structure of an HIV genome, revealing intricate patterns and structures that play a previously unappreciated role in the virus's lifecycle. This breakthrough opens doors for further research and potential antiviral drug development.
A new study found that college students with high danger invulnerability tend to decline HIV vaccines, while those with psychological invulnerability are more likely to accept them. The study suggests that efforts to promote vaccine acceptance should consider the role of invulnerability in students' health-protective behaviors.
Researchers at Yale University have recorded movies of viral activity within cells, revealing that retroviruses assemble daughter viruses at the point of contact between cells. This process is facilitated by a sticky viral protein called Env that attracts viral particles to these sites.
Researchers found SIV-infected African wild chimpanzees died prematurely and developed hallmarks of HIV-1 infection, contradicting previous assumption that infected primates wouldn't develop AIDS. Yerkes contributed key comparative data on SIV-infected and uninfected sooty mangabeys, shedding light on mechanisms behind natural immunity.
A team of researchers refuted a popular hypothesis about the failure of the Merck STEP HIV vaccine study by finding no correlation between pre-existing neutralizing antibodies and increased susceptibility to infection. The study analyzed blood samples from participants with varying degrees of pre-existing immunity to Ad5 and found that...
A study by Kaiser Permanente researchers found no racial disparities in the risk of AIDS and death among HIV-infected patients, with Hispanics experiencing better outcomes. Despite lower adherence rates, Hispanics had a statistically significant survival benefit compared to whites and blacks.
Researchers found that prolonged HAART use can better control HBV and delay or prevent liver complications. Patients with elevated liver enzymes before treatment were at increased risk of cirrhosis, highlighting the importance of monitoring these patients.
Researchers from Brown University and Harvard School of Public Health found that Brazil's efforts to treat people living with HIV/AIDS using generic medicines saved the country over $1 billion. The study also showed that the country was able to contain the virus, minimize its spread, and provide treatment to over 660,000 Brazilians.
Research team finds that women's immune system activates more strongly in response to HIV-1, leading to higher levels of CD8+ T cell activation and faster disease progression. The study suggests that targeting this pathway may lead to new treatment strategies.
The Liverpool School of Tropical Medicine is launching a £30 million initiative to strengthen health research in Africa. The program will support over 50 institutions across 18 African countries and create postgraduate scholarships for students to research health-related issues.
A team of Canadian and American researchers have identified a way to treat HIV-AIDS by targeting both viruses in the body and those hiding in immune system cells. This breakthrough opens the door for innovative therapies that differ from current approaches.
Researchers have identified a possible method for eradicating HIV infection by targeting two subsets of memory T-cells where the virus persists. The approach involves combining medications that prevent viral replication with drugs that stop infected cells from dividing.
Researchers will investigate the human innate immune system and its role in protecting against infections like HPV, which is more frequently associated with the genital tract. The study aims to understand how oral health plays a crucial role in overall health and why some people are better protected than others.
Scientists have revealed the structure of the HIV protein shell, providing a close-up look at its unique honeycomb arrangement. The discovery may help identify new ways to block HIV infection and develop novel therapeutic strategies.
The Einstein Proteomics Research Center aims to identify brain proteins responsible for neurological complications in people infected with HIV, particularly those who are also addicted to drugs. The center will investigate the mechanism of HIV infection and develop biomarkers to detect neurological disease.
Researchers at McGill University have pinpointed the key cellular machinery co-opted by HIV-1, allowing it to efficiently transport its RNA genome to the plasma membrane. This discovery opens up hopes for devising strategies to block the process and could lead to treatments to combat the virus.
Top HIV/AIDS researchers at NIAID outline a test-and-treat strategy that could reduce HIV incidence by 90% within 10 years. The proposal also involves pre-exposure prophylaxis, latent virus control, and improved prevention strategies.
Scientists have created a new protein-based microbicide that can kill HIV when used as a preventative measure. The innovation involves combining two existing proteins into a single molecule, which is then produced in large quantities using plant cells.
Researchers found that almost all HIV virus was packed into macrophages in diseased cells, which are immune cells that 'eat' invading disease agents. This discovery could lead to new treatments by targeting these infected macrophages.
Yadong Yin, an assistant professor of chemistry at UC Riverside, has been awarded the Cottrell Scholar distinction for his outstanding teaching and research in materials science. He will use a portion of his $100,000 award to support his research and attend the annual Cottrell Scholar Conference.
The study reveals that interleukin-21 is a crucial protein for the cross-talk between killer T-cells and helper T-cells. Its absence leads to failure of the immune system's anti-viral efforts, resulting in uncontrolled infections.
The Center for Proteomics and Bioinformatics at Case Western Reserve will expand its activities in HIV/AIDS research with a $989,108 grant from NIDA. The grant aims to develop reliable biomarkers for chronic immune activation during HIV disease and explore the effects of current or prior drug use on disease progression.
Researchers at UCSF found that anal human papillomavirus (HPV) is associated with a higher risk of new HIV infection in previously HIV-negative men who have sex with men. The study suggests that HPV enhances susceptibility to HIV infection through anatomical and immunological mechanisms.
Research published in PLOS Medicine found that mortality among HIV-infected people starting antiretroviral treatment (ART) is comparable to non-HIV related mortality in four sub-Saharan countries. The study analyzed data from over 2 million people with HIV and found moderate excess mortality, similar to that associated with diabetes.
The UCSF Visiting Professor Program has provided training and mentoring to 40 visiting professors from minority universities, resulting in over $50 million in research funding and 425 scientific publications. The program accelerates careers and promotes interdisciplinary approaches to HIV/AIDS prevention research.
Researchers found that HIV antibodies face obstacles in blocking infection, with a narrow window of opportunity for effective binding due to the virus's low spike density. This finding highlights potential challenges for developing an effective vaccine against HIV.
The University of Pittsburgh has received a five-year, $2.8 million grant to develop training sites in Mozambique, Brazil, and India for HIV/AIDS researchers. The program aims to equip local researchers with skills to monitor patients and combat drug resistance.
The organism Methanopyrus kandleri has a mutation that shuts down cellular activity, but an enzyme converts it back to normal. This discovery may combat viruses and provide insights into protein biosynthesis.
Researchers discover HIV counteracts human cell protection by marking proteins for rapid destruction, but not in rats. Disrupting this interaction could be a promising strategy for therapy to increase cells' protective mechanisms.
A new North American study shows that starting antiretroviral treatment earlier significantly decreases the risk of death, with a reduction of up to 94% in patients who begin treatment before their CD4+ cell count falls below 500. This finding challenges traditional guidelines and may lead to changes in medical practice.
African Americans are disproportionately affected by AIDS, yet few are pursuing HIV/AIDS research due to historical, social, and other factors. Recommendations from UCLA researchers aim to reverse the trend by supporting partnerships, retraining, mentorship, and culturally congruent research.
A potential new HIV drug, D-1mT, shows promise in reducing viral loads in monkeys with simian immunodeficiency virus when used alongside Anti-Retroviral Therapy. The researchers hope this finding could lead to a new treatment for patients not responding to current treatments.
Dr. Anthony Fauci, director of NIAID, receives IADR Honorary Membership for his significant contributions to dental research. The award recognizes his commitment to improving oral health worldwide.
A groundbreaking partnership between Einstein College of Medicine and the University of KwaZulu-Natal will focus on developing faster diagnostic tools and better chemotherapies for TB, MDR-TB, XDR-TB, and HIV. The institute aims to train a new generation of scientists in Africa and bridge the gap between bench and bedside research.
Researchers have created a new onsite method to quickly diagnose tuberculosis, reducing diagnosis time from weeks to days. The test uses bacteriophages with green fluorescence protein to detect the deadly drug-resistant strains that can mingle undetected with treatable TB strains.
Researchers at McMaster University are launching Canada's first tuberculosis (TB) vaccine clinical trial with a vaccine designed, manufactured and tested within the university. The phase 1 clinical trial will evaluate the safety of the new vaccine and assess immune responses in healthy volunteers.
Scientists have developed a new technology to isolate dozens of HIV-specific antibodies from a single individual, allowing for the first time to study natural antibody-mediated HIV neutralization. This breakthrough may prove important in understanding how effective HIV-neutralizing antibodies arise during infection.
Researchers at Rockefeller University have identified a diverse team of antibodies in slow-progressing HIV patients whose coordinated pack hunting knocks down the virus. These natural antibodies, produced by six people infected with HIV, show limited neutralizing ability when alone but become effective when combined.
Researchers at Rutgers University have made significant progress in developing an HIV vaccine by identifying a crucial part of the virus that is common to most varieties. They created a method to immunize animals with this target, resulting in antibodies that can stop a diverse set of HIV isolates.